June 9, 2017 03:23 PM EDT
R&D

Tri­al ob­servers say ‘game over’ for XBiotech's failed PhI­II can­cer study, the lat­est in a long line of set­backs

John Carroll

Editor & Founder

There’s more bad news to re­port for XBiotech $XBIT.

A few weeks af­ter Eu­ro­pean reg­u­la­tors snubbed the com­pa­ny’s ap­pli­ca­tion to start mar­ket­ing its du­bi­ous …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times